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Abstract 
Engineered nanoparticles (NPs) offer site‑specific delivery, deposition and cellular uptake due to their unique phys‑
icochemical properties and were shown to modulate immune responses. The respiratory tract with its vast surface 
area is an attractive target organ for innovative immunomodulatory therapeutic applications by pulmonary admin‑
istration of such NPs, enabling interactions with resident antigen‑presenting cells (APCs), such as dendritic cells and 
macrophages. Depending on the respiratory tract compartment, e.g. conducting airways, lung parenchyma, or lung 
draining lymph nodes, APCs extensively vary in their number, morphology, phenotype, and function. Unique char‑
acteristics and plasticity render APC populations ideal targets for inhaled specific immunomodulators. Modulation of 
immune responses may operate in different steps of the immune cell‑antigen interaction, i.e. antigen uptake, traf‑
ficking, processing, and presentation to T cells. Meticulous analysis of the immunomodulatory potential, as well as 
pharmacologic and biocompatibility testing of inhalable NPs is required to develop novel strategies for the treatment 
of respiratory disorders such as allergic asthma. The safe‑by‑design and characterization of such NPs requires well 
coordinated interdisciplinary research uniting engineers, chemists biologists and respiratory physicians. In this review 
we will focus on in vivo data available to facilitate the design of nanocarrier‑based strategies using NPs to modulate 
pulmonary immune responses.
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Background
The human respiratory tract provides a vast epithelial 
surface area for air conduction and gas-exchange with a 
combined surface area that is about 150 m2. In particular, 
the gas exchange region provides the major part of sur-
face, where the structural barrier between air and blood 
is reduced to a mean arithmetic thickness of 2.2  μm or 
thinner tissue layers in the alveoli [1]. The vast surface 
and direct contact with environment makes lung the 
most important portal of entry for inhaled xeniobiot-
ics such as particulate matter (reviewed in [2]). This has 
raised concerns that particles may cause respiratory 
disease or trigger adverse effects as seen with ambient 
combustion-derived particles recognized as an impor-
tant cause of cardiovascular morbidity and mortality in 
areas with air pollution [3–5]. On the other hand, the 
unique lung characteristics render this organ ideal for 
novel biomedical applications by inhalation of specifically 
designed nanomaterials [6]. Nano-sized carriers [e.g. 
mainly nanoparticles (NPs) with all three dimensions 
below 100  nm (ISO/TS, 2008)] have been proposed as 
promising novel diagnostic, therapeutic, and vaccination 
approaches for a variety of human diseases [7–9].
Drug delivery through the pulmonary route offers sev-
eral advantages over oral or parenteral delivery. This is 
primarily due to the presence of a dense vasculature, the 
circumvention of the first pass effect, and a lower concen-
tration of drug-metabolizing enzymes in the lung com-
bined with the highly dispersed nature of an aerosol [10, 
11]. Furthermore, size-dependent deposition and size-
dependent uptake by specific immune cell subsets (as 
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discussed later) in the pulmonary compartment may lead 
to modulation specific downstream immune responses 
with reduced side-effects due to targeted delivery by NPs. 
Novel NPs may be employed to deliver drugs or may act 
as immunomodulators, either on the entire lung surface 
or by targeting a particular cell population localized in a 
specific compartment of the respiratory tract. Knowledge 
about the anatomical compartments in the respiratory 
tract and resident cells is a prerequisite to understand 
the interplay between APCs and inhalable NPs. In addi-
tion, each NP type requires thorough characterization 
and testing in  vitro, before being considered for animal 
experimentation and clinical applications. Characteri-
zation begins during and immediately after synthesis of 
NPs to monitor physicochemical properties, size, shape 
and stability. In a subsequent step, cell-free assays can 
be employed to investigate how particles interact with 
constituents of biological solutions, such as free pro-
teins and enzymes [12, 13]. Mechanisms of particle-cell 
interaction and cytotoxicity are investigated by in  vitro 
experiments using either cell mono-cultures or more 
advanced and complex 3D co-culture systems that simu-
late specific human organs or organ compartments [13]. 
To study effects of NPs on the entire organism, in  vivo 
animal models are necessary in species that represent 
appropriate models for the human anatomy, physiol-
ogy, and immunology as closely as possible. Extensive 
short, intermediate and longterm in  vivo characteriza-
tion of both unwanted biological effects and efficacity 
of particle are a prerequisite before clinical testing can 
be performed. Such a cascade of characterization of bio-
compatibility and immunogenicity on multiple levels of 
increasing complexity will allow the development of NPs 
of acceptable safety and accurately defined effects regard-
ing targeting, interplay with target cells/tissues and per-
sistence. In particular safety regarding toxicological and 
immunomodulatory effects of newly developed biomedi-
cal NPs should be of major concern.
In this review we will summarize the anatomy of the 
respiratory tract regarding the different immune cell 
subsets which are populating its diverse compartments. 
Furthermore, we will focus on recently emerged in vivo 
models to monitor the immunomodulatory potential of 
biomedical NPs while discussing characteristics of poten-
tial biomedical NPs, which are important in order to 
modulate immune responses in the lung.
General anatomy of the respiratory tract
As previously outlined, the lung provides an attractive 
portal of entry in the human body for non-invasive appli-
cations using biomedical NPs. Detailed knowledge on the 
macroscopic structure of the lung anatomy, i.e. different 
compartments; and in particular the distribution and 
function of immune cells within different compartments 
of the respiratory tract is crucial to develop and engineer 
specific inhalable NPs. The human respiratory tract is 
structurally designed for gas exchange in the human body 
through a huge internal surface area of about 150  m2 
(i.e. alveoli and airways) closely enmeshed with a dense 
capillary network [1]. The respiratory tract is anatomi-
cally subdivided into four regions: (1) the extra thoracic 
region comprising the anterior nose and the posterior 
nasal passages, larynx, pharynx and mouth; (2) the bron-
chial region consisting of the trachea and bronchi; (3) the 
bronchiolar region consisting of bronchioles and termi-
nal bronchioles; and finally (4) the alveolar-interstitial 
region consisting of respiratory bronchioles (bronchioles 
with some alveoli apposed), the alveolar ducts and sacs 
with their alveoli and the interstitial connective tissue, 
inside the interalveolar septa.
The epithelial tissue changes its architectural and 
cellular characteristics from the upper airway to the 
periphery. Beginning at the trachea/bronchi, the airway 
epithelium is pseudostratified with ciliated epithelial 
cells, i.e. mucocilary escalator, and at the level of smaller 
bronchioles it is of cuboidal appearance. Toward the lung 
periphery, the alveoli are lined by squamous cells, the 
alveolar type I epithelial cells which cover about 95% of 
the surface and share a basement membrane with the 
endothelial cells covering the pulmonary capillaries, 
and also contain alveolar type II epithelial cells, which 
secrete lung surfactant (surface active agent) to prevent 
alveolar collapse [14, 15]. The structural barrier between 
air and blood is reduced to a mean arithmetic thick-
ness of 2.2 μm or thinner tissue layers in the alveoli [1]. 
More than 40 different cell types, amongst others differ-
ent types of epithelial cells, endothelial cells, fibroblasts, 
nerve cells, lymphoid cells, gland cells, dendritic cells and 
macrophages, add to the complexity of the epithelium in 
the lung. All four regions in the respiratory tract contain 
lymphatic tissue or specific components of it [14].
There are approximately 400 million alveoli in the lungs 
[16], with a combined surface area that is about 140 m2 
and with an alveolar epithelium which can be as thin as 
0.1  μm [1, 15]. The interstitium of the alveolar septum 
is for most parts extremely thin and endothelial cells, 
which cover the inner surface of the capillaries, fuse with 
basement membranes of epithelial cells to minimize the 
air-blood barrier. At the thicker parts, where the base-
ment membranes of endothelial and epithelial cells are 
separated, elastic fibers, collagen fibrils bundles as well 
as fibroblasts are present in the extracellular matrix. This 
large surface area, combined with an extremely thin bar-
rier between the pulmonary lumen and the capillaries, 
creates conditions that are well suited for efficient gas 
transfer [14].
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Lung barriers and particle clearance
A series of structural and functional barriers protect the 
respiratory system against both harmful and innocuous 
xenobiotics [17]. The airway mucosa, with its respira-
tory epithelium sealed by apically localized tight junction 
complexes, provides a mechanical barrier that protects 
against effects of inhaled and on the lung cell surface 
deposited xenobiotics. Furthermore, ciliated epithelial 
cells and mucus producing goblet cells, together with 
locally produced secreted immunoglobulins (mainly 
IgA), provide effective mechanisms for mucociliary clear-
ance of inhaled particulate antigens [18]. In addition, 
airway epithelial cells have key roles in the regulation of 
lung homeostasis by secretion of a range of regulatory 
and effector molecules (e.g. mucins, surfactant proteins, 
complement and complement cleavage products, antimi-
crobial peptides) that are involved in front-line defence 
against pathogens [19].
The clearance kinetics in the lung periphery is much 
slower due to the absence of mucociliary action, and 
particles are eliminated by (1) phagocytosis with subse-
quent transport by macrophages, (2) dendritic cells with 
trafficking to draining lymph nodes, as well as (3) direct 
translocation via the air-blood tissue barrier into the cir-
culation. All these mechanisms by which the particles are 
eliminated from the inner surface of the respiratory tract 
have to be taken into account for the design of new NPs 
[20].
The immune system in the respiratory tract
APCs such as alveolar and interstitial macrophages, as 
well as dendritic cells (DCs) (Fig.  1), play an important 
role in the regulation of the immune response.
Respiratory tract macrophages play an important 
role in the maintenance of immunological homeosta-
sis and host defense. In the lungs the key population is 
composed of alveolar macrophages. Under steady state 
conditions, the most important function of alveolar mac-
rophages is phagocytosis and sequestration of antigen 
from the immune system to shield local tissues from the 
development of specific immune responses [21]. Alveolar 
macrophages have been shown to take up most of the par-
ticulate material that is delivered intranasally [22]. Since 
alveolar macrophages do not migrate to the lung draining 
lymph nodes [23], their antigen presentation capabilites 
are limited to interact with local effector T cells only, in 
contrast to pulmonary dendritic cells which, as profes-
sional antigen presenting cells, migrate to the lymph 
nodes in order to activate naive T cells and to direct their 
differentiation into effector T cells, as described later. 
Besides clearance of inhaled particulates, macrophages 
are involved in diverse functions that  are achieved by 
the plasticity of these cells that, depending on signals 
present in their microenvironment, can polarize into 
a plethora of different phenotypes [24, 25]. Cytokines, 
such as interferon (IFN)-γ and tumor necrosis factor 
(TNF)-α, or bacterial products, such as lipopolysaccha-
ride (LPS), induce polarization of macrophages into a 
proinflammatory phenotype through the transcription 
factor IFN regulatory factor 5 (IRF5). Such macrophages 
were conventionally named M1-dominant macrophages 
and release proinflammatory cytokines interleukin (IL)-
12, IL-1β, and TNF-α. They are thus important in host 
defense against intracellular pathogens [24, 26]. Further-
more, macrophages induced by the proallergic asthma 
cytokines IL-4 and IL-13, in the past conventionally also 
known as M2 macrophages that are important in wound 
healing and host defense against helminth infections. 
This macrophage subset is characterized by upregulation 
of the mannose receptor (CD206) and, in mice, produc-
tion of the chitinase-like protein YM1. However, recent 
literature has challenged the existence of an M1 and 
M2 paradigm of macrophage activation and proposed a 
more complex system of macrophage polarization [27]. 
Another macrophage phenotype consists of anti-inflam-
matory macrophages that are induced by compounds and 
mediators such as corticosteroids, IL-10, or prostaglan-
din E2 PGE2. Such anti-inflammatory macrophages are 
also characterized by upregulation of CD206, but pro-
duce the anti-inflammatory cytokine IL-10 [28].
Fig. 1 Interactions of DCs and T cells in the airway mucosa visualized 
by laser scanning microscopy. Micrograph shows a scanned area from 
a cross section through a trachea (rat). T cells (CD3, blue) are visible 
closely interacting with DCs (MHC class II, green) inside the airway 
epithelium (EP) and the lamina propria (LP)
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The mucosa of the airways and the lung parenchyma 
also contains dense networks of DCs that develop early 
in life [29]. DCs are professional APCs that link innate 
and adaptive immunity, and therefore occupy a key role 
in regulating the body’s immune responses [30]. They are 
strategically positioned for antigen uptake both within 
and directly below the surface epithelium and extend 
protrusions into the airway lumen [31], or the alveolar 
space [32] similar to what has been demonstrated for 
DCs in intestinal tissue where DCs have been shown to 
form tight junction complexes with epithelial cells [33]. 
This characteristic suggests that DCs can sample directly, 
both from the airway lumen and the alveolar space [32] 
through the intact epithelium [31] by the expression of 
adherens and tight junction proteins which might help to 
preserve the epithelial integrity in a trans-epithelial net-
work [34]. Morphologically characterized by dendrite-
like projections DCs are the most potent APC population 
able to provide T cell activation (Fig. 1) [35].
Potential pathogens are ‘sensed’ through pattern recog-
nition receptors (PRRs) that interact with pathogen asso-
ciated molecular patterns (PAMPs), triggering innate and 
adaptive immunity [36]. In DCs, activation through the 
PRRs leads to upregulation of the chemokine receptor 
CCR7 (CD197; the ligand is CCL19/ECL) that is essen-
tial for DC migration from the site of pathogen encounter 
to lymph nodes, where activation of naive T cells occurs. 
In this process of trafficking to the lymph nodes DCs dif-
ferentiate from a so-called ‘immature’ state (high capac-
ity for antigen uptake, low capacity for T cell activation) 
to a ‘mature’ state (low capacity for antigen uptake, high 
capacity for T-cell activation) [37]. Following migration 
to lymph nodes, DCs face their most important task: that 
is to instruct T cells to respond to presented antigen in 
the most appropriate way. The type and activation state 
of the DC, the dose of antigen, as well as the nature of 
concomitant micro-environmental factors present at 
the time of antigen encounter determine the nature of 
the resulting T cell response [37]. Conventionally, three 
different outcomes for effector T cells have been distin-
guished: T helper 1 (Th1), T helper 2 (Th2) and regula-
tory T cells (Treg). A Th1 response is characterized by the 
production of IFN-γ and TNF by T cells. It is the normal 
outcome after an exposure of DCs to viruses or bacte-
ria. It is also the basis of the delayed type hypersensitiv-
ity reaction. Th2 differentiation usually occurs following 
contact with extracellular parasites and involves the pro-
duction of cytokines IL-4, IL-5, IL-9, and IL-13 resulting 
in IgE production and accumulation of eosinophils and 
mast cells. Furthermore, in allergic asthma, as nonpatho-
genic environmental antigens are able to induce an inap-
propriate Th2 response and become allergens, such as the 
house dust mite allergen Der p1. The third outcome is the 
induction of regulatory T cells that produce immunosup-
pressive cytokines such as IL-10 or TGF-β. This describes 
probably the most prevalent response in steady-state 
conditions, as it forms a constant safeguard against the 
induction of inappropriate inflammatory reactions to 
harmless antigen [37]. It has become increasingly evi-
dent that T cell functions are considerably more complex 
and heterogeneous than originally assumed. In particu-
lar, the potential key role of Th17 cells in disease patho-
genesis has been described. As an example, some asthma 
patients have been described to develop a more type 17 
associated disease with dominance of neutrophils rather 
than eosinophils [38]. An additional conceptual develop-
ment has emerged with the role of airway epithelial cells 
in driving the selection of disease-related T cell pheno-
types through the expression of potent T cell modulatory 
molecules (discussed in [19]).
T cells are also found in varying numbers in the airways 
and the lung parenchyma. In the airways they are found 
intraepithelially and within the underlying lamina propria. 
As in the gut, most intraepithelial T cells express CD8, 
whereas CD4+  T cells are more frequently localized the 
lamina propria. Both subsets mainly have an effector- and/
or memory-cell phenotype [19]. Both in vitro and in vivo 
studies have shown that T cell proliferation upon NP treat-
ment can be affected [8, 22, 39–41]. T cells are thus prom-
ising targets for future therapies using biomedical NPs.
The lamina propria of the airways also contains mast 
cells and plasma cells (mainly producing polymeric IgA) 
and some loosely distributed B  cells. Aside from their 
central role in antibody production, it is possible that 
B cells also contribute to local antigen presentation, given 
the recent demonstration of such a function for B  cells 
in the lymph nodes that drain the lungs [42]. Figure  2 
shows a simplified illustration of the innate and adaptive 
immune response in the respiratory tract.
Particle deposition in different lung compartments
According to the particle size, it can be predicted in 
which compartment particles will be predominantly 
deposit in the lung [10, 43]. Larger particles (1–10  μm) 
preferentially deposit in trachea and bronchi, whereas 
smaller particles (i.e. NPs) tend to deposit in in the 
deeper regions of the lung (i.e. small airways and alve-
oli). Inhaled particles may be deposited in the lung by 
impaction, sedimentation and diffusion as described 
in detail in [44]. While impaction is generally observed 
with particles greater than 5  μm, sedimentation is seen 
with particles with sufficient mass and a size of 1–5 μm 
in diameter. Finally diffusion is observed mainly with the 
smallest particles (Table  1). Therefore, solely depend-
ing on the size of particles or aerosol droplets, differ-
ent compartments of the respiratory tract and specific 
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subpopulations of immune cells may be targeted. In addi-
tion a recent study has shown that depending on size and 
charge particles deposited on the respiratory mucus are 
either locally trapped or can diffuse freely [45].
A large number of different studies in the recent years 
has also demonstrated that characteristics of NPs like 
size, shape, surface charge, and surface modification all 
play an important role in affecting the fate of the particles 
in the respiratory tract with particle size, surface charge 
and surface modification being among the most impor-
tant. Deposition in the respiratory tract depends, how-
ever, mainly on particle size due to the fact that different 
mechanisms of particle deposition are defined based on 
this characteristic.
Based on size-dependent pulmonary deposition NPs 
can be used to primarily target distal lung compartments 
for prolonged persistence, since in these anatomical areas 
there is only slow removal by alveolar macrophages com-
pared to the proximal lung compartments like the con-
ducting airways. Prolonged persistence allows NPs to 
interact with cells of interest for a longer time in order 
to become effective locally by remaining in the lung com-
partment or systemically by crossing the air-blood bar-
rier. In particular the interaction of NPs with pulmonary 
immune cells is of great interest, since NPs can be easily 
applied in the lungs and immediately get in contact with 
different cells of the immune system after deposition. A 
number of recent studies has characterized how inhaled 
Fig. 2 Simplified schematic presentation of the human respiratory immune system. The upper respiratory epithelium, lining the inner surface of 
the trachea, bronchi and bronchioles, is composed of a pseudostratified layer of ciliated cells, mucus‑producing cells and basal cells, and is respon‑
sible for rapid clearance of inhaled particulate antigen with the mucociliary escalator. The distal regions of the lung epithelium, the alveolar septa, 
represent the site of the gas exchange. In both regions, macrophages are located at the apical side of the epithelial layer and protect it from the 
inhaled antigen cells by phagocytosis. Dendritic cells will capture antigens, process and present antigen peptide to naive T cells, and trigger their 
differentiation into antigen‑specific effector T cells. Figure as shown in and reprinted with permission from Nanomedicine (Futuremedicine)
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NPs affect immune cells in the lung and provide valua-
ble information for the development of novel biomedical 
tools for pulmonary delivery.
Immunomodulatory potential of NPs in in vivo 
models
The highly complex organization of the pulmonary 
immune system characterised by a multitude of cell–cell 
interactions across different respiratory tract compart-
ments, highlights the essential requirement to investigate 
the fate and effects of inhalable biomedical NPs. Hence 
in  vivo models are a crucial step in the optimization of 
potential biomedical NPs following initial development 
through in  vitro investigations [13] before clinical stud-
ies can be considered. In the following paragraph prom-
ising nanocarriers and treatment strategies, which have 
been tested in in vivo models, i.e. mainly rodents, are dis-
cussed and compared.
Screening for NP characteristics relevant for transloca-
tion in the respiratory tract, Choi et al. utilized different 
NPs by varying material, size, shape, as well as surface 
charge, and correlated these properties with translocation 
in the body and adverse health effects, after lung instilla-
tion in rat models [46]. Briefly, administration of non-cat-
ionic NPs with a size of approximately 30 nm or smaller 
resulted in a maximal translocation to mediastinal lymph 
nodes and the bloodstream due to insufficient clearance. 
The authors suggested to employ chemical modifications 
to adapt size and the charge of NPs, so the adverse health 
effects may be minimized. Focusing on particle size, we 
employed in a recently reported in vivo study polystyrene 
(PS) NPs intra-nasally in mice, and demonstrated size-
dependent uptake, trafficking, and modulation of down-
stream immune responses [22]. Compared to larger NPs, 
those with a diameter of 20–50  nm were preferentially 
captured and trafficked by pulmonary DCs to lung drain-
ing lymph nodes, while very low or no lymphatic drainage 
was observed with any other particle size. In particular, 
20 nm PS NPs co-administered together with the model 
antigen ovalbumin (OVA) induced significantly enhanced 
activation of antigen-specific T cells, compared to results 
obtained with larger 1000 nm particles [22]. In contrast, 
a similar study done by Hardy and co-workers showed 
a prophylactic inhibitory effect of 50  nm neutral amino 
acid glycine (PS50G) NPs: Intratracheally instilled PS50G 
NPs did not exacerbate but instead inhibited key features 
of allergic airway inflammation including lung airway 
and parenchymal inflammation, airway epithelial mucus 
production, and serum allergen-specific IgE and aller-
gen-specific Th2 cytokines in the lung-draining lymph 
node after allergen challenge 1  month later. Further-
more, PS50G NPs themselves did not induce any inflam-
matory response or oxidative stress in the lungs. Finally, 
PS50G NPs suppressed the ability of CD11bhi DCs in 
the draining lymph nodes of allergen-challenged mice to 
induce proliferation of OVA-specific CD4+ T cells [41]. 
A follow-up study of the same group using the same 
PS50G (50  nm) and larger PS500G (500  nm) nanopar-
ticles, investigated the uptake by antigen presenting cell 
populations in the lung parenchyma and the lung drain-
ing lymph nodes following intra-tracheal instillation in 
naive mice. It was found that PS50G were preferentially 
taken up by alveolar and non-alveolar macrophages, B 
cells, and CD11b+ and CD103+ DC in the lung. How-
ever, in the lung draining lymph nodes, only DCs were 
found to contain particles, demonstrating transport of 
NPs to the lymph nodes exlusively by DCs. Consisten 
with our findings, this study excluded particle transloca-
tion via lymphatic drainage. However, both particle sizes 
decreased frequencies of stimulatory allergen-laden DC 
in the lung draining lymph nodes, with the smaller par-
ticles having the more pronounced effect. The authors 
from these studies concluded that in allergic airway 
inflammation PS50G but not PS500G significantly inhib-
ited adaptive allergen-specific immunity [47]. Another 
study with results similar to our findings investigated the 
trafficking of intranasal instilled 500  nm PS beads from 
the respiratory tract to the mediastinal lymph nodes, in 
which the majority of particles was captured by alveolar 
macrophages, but particles were also detected in a small 
number of DCs that had migrated to the T cell—rich 
areas of the mediastinal lymph nodes [23]. Additional 
studies have shown that polylactid-co-Glycolid (PLGA) 
NPs (approximately 200  nm) and dendrimers (<10  nm) 
may be functionalized with siRNA or drugs while sur-
face charge can be controlled during synthesis of NPs 
[48–50]. Focusing on pulmonary deposition following 
inhalation, Taratula et  al. [51] successfully delivered a 
high concentration of inhalable lipid-NP-based drug to 
the respiratory tract of mice. In this study, pulmonary 
deposition was more efficient compared to intravenous 
injection of the same drug, in terms of organ distribu-
tion, lung tumor targeting, and anti-cancer activity. These 
studies demonstrate a significant effect of particle size in 
the modulation of innate and adaptive immune responses 
in the respiratory tract. Particle size has therefore to be 
Table 1 Correlation between compartments of lung depo-
sition, the mechanism of deposition and particle size
Location Size (μm) Mechanism
Primary bronchi 5–10 Impaction
Secondary bronchi 1–5 Sedimentation
Bronchioles 1–3 Sedimentation
Alveoli 0.5–1 Brownian motion
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taken in consideration for the development of biomedical 
carriers for the use in pulmonary applications.
As already discussed above, not only particle size 
but also surface charge of an engineered NP may affect 
pulmonary immune cells and modulate downstream 
immune responses. In order to address how surface 
charge of a pulmonary administered NP may affect 
its fate and modulate a specific immune response, we 
employed modified gold NPs (AuNPs) (Fig.  3). The 
AuNPs were coated with polyvinyl alcohol (PVA) con-
taining either positively (NH2) or negatively (COOH) 
charged functional groups [52]. Following intra-nasal 
instillation in a mouse model, all pulmonary APC sub-
sets preferentially took up positively charged AuNPs, 
compared to negatively charged AuNPs. Also, positively 
charged AuNPs generated an enhanced ovalbumin-
specific CD4+ T cell stimulation in lung draining lymph 
nodes compared to negatively charged AuNPs. An 
additional salient finding in this study was that intact 
positively charged AuNPs were necessary, as immune 
responses were not affected when the positively charged 
polymer was utilized alone. Another recent study also 
demonstrated improved therapeutic effects of a partic-
ulate biomedical carrier compared to its soluble coun-
terpart: In this study solid lipid nanoparticles (SLNs) of 
Yuxingcao essential oil (YEO) with different particle size 
(200, 400 and 800  nm) were prepared using Compritol 
888 ATO as lipid and polyvinyl alcohol as an emulsifier. 
Following intra-tracheal administration in rats, YEO 
loaded SLNs not only prolonged pulmonary retention 
up to 24 h, but also increased area under the curve val-
ues (15.4, 18.2 and 26.3  μg/g  h for SLN-200, SLN-400 
and SLN-800, respectively) by 4.5–7.7 folds compared to 
the intra-tracheal dosed YEO solution and by 257–438 
folds to the intravenously dosed YEO solution, respec-
tively. These results demonstrated a promising inhalable 
particulate carrier with improved local bioavailability 
[53]. Furthermore, a similar study showing effects of 
surface charge following administration to the lung 
was conducted to understand the biological impact of 
superparamagnetic iron oxide NPs (SPIONs) and their 
surface-modification with polyethylene glycol having 
either negative (i.e. carboxyl) or positive (i.e. amine) 
functional groups in a 1-month longitudinal study using 
a mouse model. Genetic assessment revealed enhanced 
expression of chemokine ligand 17 (CCL-17) and IL-10 
biomarkers following SPIONs administration compared 
to surface-modified NPs. However, SPIONs with car-
boxyl terminal showed a slightly prominent effect com-
pared to amine modification [54]. A further study used 
cationic carbon dots for pulmonary delivery of DNA. 
Administration of particle-DNA complexes to mouse 
lungs demonstrated that these new carriers achieved 
similar efficiency but lower toxicity compared to GL67A, 
a golden standard lipid based transfection reagent for 
gene delivery to the lungs. The authors suggested that 
post-functionalization of these nanoparticles with poly-
ethylene glycol (PEG) or targeting moieties should even 
improve their efficiency and in  vivo biocompatibil-
ity [55]. Another recent in  vivo study performed with 
hydrogel rod-shaped NPs of different surface charge also 
confirmed enhanced uptake of positively charged NPs 
by alveolar macrophages and different subsets of pul-
monary DC, with enhanced trafficking to lung draining 
lymph nodes, as compared to negatively charged NPs. 
The authors concluded that cationic NPs are endowed 
with an enhanced immunomodulatory potential in the 
respiratory tract [56]. All these in vivo findings underline 
Fig. 3 CD4+ T cell proliferation in lung draining lymph nodes was 
measured after intra nasal instillation of positively charged (Au+; 
NH2) and negatively charged (Au−; COOH) gold NPs or polymer 
shells alone followed by ovalbumin in a mouse model of ovalbumin 
induced experimental allergic airways disease. Positively charged 
gold NPs induced enhanced ovalbumin specific T cell proliferation 
compared to controls (non‑exposed), negatively charged gold NPs or 
positively charged polymer alone. These findings highlight the impor‑
tance of surface charge of a biomedical NP in modulating a specific 
adaptive immune response. Adapted from [11]
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that size, surface charge and intact conformation of 
engineered NPs play an important role in modulating 
downstream immune responses in the respiratory tract 
[11]. The studies discussed above highlight that differ-
ent attributes of NPs such as size and surface charge 
may become important triggers to re-program adap-
tive immune responses in the respiratory tract. Inhal-
able NPs may therefore be designed to specifically 
modulate pulmonary immune responses, either towards 
an immune-therapy to reprogram allergic responses, 
or vaccination to generate protective immunity against 
a respiratory pathogen. To prevent triggering of exces-
sive inflammatory responses that may jeopardise gase-
ous exchange, meticulous development of inhalable NPs 
through in depth characterisation of in vivo effects is the 
final, but most crucial step in pre-clinical development.
Conclusions
The lung with its extensive internal surface harboring 
different immune cell populations, provides a non-inva-
sive and promising target organ for novel therapies with 
inhalable nanoparticles. NP engineering approaches is a 
promising technique for non-invasive and cost-effective 
pulmonary drug delivery to treat respiratory tract dis-
order. Specific NP properties such as material, size and 
surface modification that can be used to stimulate or to 
inhibit a specific immune reaction may be specifically 
designed for the treatment of immune disease, such as 
allergic asthma. In order to achieve this, close collabora-
tion and interdisciplinary research between physicians, 
biologists, chemists and material scientists is essential. 
Furthermore, careful design, thorough characterization 
and process control in the entire NP synthesis procedure 
is required in order to assure high-quality NP batches 
with repeatedly reproducible and accurate results. 
Sophisticated approaches using relevant animal models 
can play a major role in this development since they can 
provide straight-forward and reliable data which can be 
the baseline of such developments.
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